Phase 2b multi-center, randomized, dose-ranging, double-blind, parallel clinical trial of Halo-Lido cream for the treatment of hemorrhoids
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Halobetasol/Lidocaine (Primary)
- Indications Haemorrhoids
- Focus Therapeutic Use
Most Recent Events
- 10 Jul 2024 According to a Citius Pharmaceuticals Inc media release, an end of Phase 2b trial meeting with the FDA was held to discuss the positive data for Halo-Lido. The data showed a meaningful reduction in symptom severity when compared to individual components alone.
- 14 Feb 2024 According to a Citius Pharmaceuticals Inc media release, the company has scheduled end of Phase 2b trial meeting with FDA in calendar 2Q 2024 to discuss next steps in development of Halo-Lido for the treatment of hemorrhoids.
- 14 Aug 2023 According to a Citius Pharmaceuticals Inc media release, company extending financial runway through August 2024 with $15 million in capital raised through a registered direct offering of common stock and warrants at a purchase price of $1.20 per share on May 8, 2023.